Oct 8, 2007 - - Akesis Pharmaceuticals, Inc. (OTC/BB: AKES), an emerging diabetes drug-development company, announced that it has filed its first Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead product candidate AKP-020, a novel vanadium compound that is expected to show considerable potential as a treatment for patients with Type 2 Diabetes... Akesis' Press Release -Tuesday, October 9, 2007
Akesis Pharmaceuticals , IND for Phase IIa Trial of AKP-020 to Treat Type 2 Diabetes
Oct 8, 2007 - - Akesis Pharmaceuticals, Inc. (OTC/BB: AKES), an emerging diabetes drug-development company, announced that it has filed its first Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead product candidate AKP-020, a novel vanadium compound that is expected to show considerable potential as a treatment for patients with Type 2 Diabetes... Akesis' Press Release -
